NCT00004180 2023-06-26
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Phase 2 Completed
Dana-Farber Cancer Institute
Université de Sherbrooke
Bayer
University of Pittsburgh
GlaxoSmithKline
Canadian Network for Observational Drug Effect Studies, CNODES
M.D. Anderson Cancer Center
Vanderbilt University
Genentech, Inc.
GlaxoSmithKline
Exelixis
Massachusetts General Hospital
National Cancer Institute (NCI)